SRP3160
sRank Receptor human
recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Synonyme(s) :
ODAR (osteoclast differentiation and activation receptor), TNFRSF11A, TRANCE Receptor
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
NACRES:
NA.32
UNSPSC Code:
12352200
Form:
lyophilized
Assay:
≥98% (HPLC), ≥98% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
19.3 kDa
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderbiological source
human
recombinant
expressed in E. coli
assay
≥98% (HPLC), ≥98% (SDS-PAGE)
form
lyophilized
potency
30-50 ng/mL ED50
mol wt
19.3 kDa
packaging
pkg of 100 μg
technique(s)
cell culture | mammalian: suitable
impurities
<0.1 EU/μg endotoxin, tested
color
white
UniProt accession no.
shipped in
wet ice
storage temp.
−20°C
Gene Information
human ... TNFRSF11A(8792)
General description
Soluble receptor activator of nuclear factor-κB (sRANK) also known as TNF receptor superfamily member 11a (TNFRSF11A), is encoded by the gene mapped to human chromosome 18. The encoded protein belongs to the tumor necrosis factor (TNF) receptor superfamily. RANK is widely expressed in variety of tissues, including skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas. Recombinant human sRANK receptor is a 19.3kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).
Biochem/physiol Actions
Soluble receptor activator of nuclear factor-κB (sRANK) plays a vital role in bone remodeling and fracture repair. Alterations in the RANK signaling increase the risk of susceptibility to expansile osteolysis and Paget disease of bone (PDB2). In addition, mutation of the gene coding for RANK/RANKL/OPG has also been observed in various skeletal disorders such as osteoporosis, glucocorticoid-induced bone loss, multiple myeloma, and rheumatoid arthritis. Binding of RANKL to its receptor RANK triggers the formation and differentiation of osteoclasts with the help of various transcription factors involved in modulation of osteoclastogenesis. RANK/RANKL/OPG might act as a potent therapeutic target for bone diseases.
Physical form
Lyophilized from 10 mM Sodium Phosphate, pH 7.2.
Preparation Note
Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.
Other Notes
MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGPDEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG YHWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFSSTD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
Hughes AE
Nature Genetics, 24(1), 45-48 (2000)
Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.
Colombini A
International Orthopaedics, 35(5), 777-782 (2011)
RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T
Trends in Molecular Medicine, 12(1), 17-25 (2006)
CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D
The Journal of Clinical Endocrinology and Metabolism, 92(12), 4514-4521 (2007)
H Hsu et al.
Proceedings of the National Academy of Sciences of the United States of America, 96(7), 3540-3545 (1999-03-31)
A receptor that mediates osteoprotegerin ligand (OPGL)-induced osteoclast differentiation and activation has been identified via genomic analysis of a primary osteoclast precursor cell cDNA library and is identical to the tumor necrosis factor receptor (TNFR) family member RANK. The RANK
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique